La vendita allo scoperto per Enovis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Enovis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Enovis (NYSE:ENOV) Azioni, Report sulle vendite allo scoperto

Enovis

Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.

Enovis Corp

Enova International Inc

Enovix Corp

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $65 price target.

News

Price Target

Reiteration

Analyst Ratings

ENOV

Needham Reiterates Buy on Enovis, Maintains $65 Price Target

Earnings

Guidance

Health Care

General

Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71

Enovis Narrowed Its Revenue Range And Adjusted  EBITDA  Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.62 by 17.74 percent. The company reported quarterly sales of $505.22 million which beat the analyst consensus estimate of $504.07 million by 0.23 percent. This is a 21.00 percent increase over sales of $417.52 million the same period last year.

Enovis Q3 2024 Adj EPS $0.73 Beats $0.62 Estimate, Sales $505.22M Beat $504.07M Estimate

JMP Securities initiated coverage on Enovis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>), a medical technology company focusing on orthopedics.
The analyst adds that the company sells a broad portfolio of products, many of which were added via selective acquisitions (around 20 over the last 4.5 years). The analyst views M&amp;A as a core competency.
The company&#8217;s product offerings span large joint reconstruction implants, extremity solutions, and various prevention and recovery franchises.
These lines enable comprehensive care, addressing patient needs before, during, and after injury or trauma. This broad portfolio provides the scale to compete with major MedTech players and unlocks extensive opportunities for brand expansion.
Earlier this year, Enovis completed the acquisition of LimaCorporate S.p.A, a private global orthopedic company focused on restoring motion via a portfolio of implant solutions, for an enterprise value of approximately 800 million euros <a target="_blank" href="https://www.benzinga.com/markets/equities/23/09/34859649/big-moves-in-orthopedics-enovis-seals-800m-deal-to-acquire-limacorporate" rel="noreferrer noopener">(around $850 million)</a>.
This second-largest deal in the company&#8217;s history bodes well for the company.
Management noted that channel integration was 100% complete in the U.S. and 70% outside the U.S., revenues were tracking slightly better than original guidance, and cost synergies of over $40 million in year three remain intact, with $10-$15 million accruing this year.
In the second quarter, Enovis reported sales of $525 million, up 23% on a reported basis and 5% on a Comparable sales <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40213609/enovis-announces-second-quarter-2024-results" rel="noreferrer noopener">basis year-over-year</a>.
&#8220;We continue to execute against our plan for the year and are off to a great start integrating our transformational Lima acquisition,&#8221; said Matt Trerotola, CEO of Enovis.
The analyst views the LimaCorporate deal as largely derisked. Peak dis-synergy of ~$10 million occurred in the second quarter of 2024, which is now in the rearview mirror.
JMP analyst initiates with a Market Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/ENOV/analyst-ratings" rel="noreferrer noopener">price target of $62</a>.
Despite a roughly 25% year-to-date decline in the stock and its current valuation at approximately 12x 2026 EPS estimates, JMP Securities says the market has yet to fully recognize the advantages of the acquisition and the progress made in its integration.
Given these factors, the analyst sees Enovis as undervalued compared to its mid-cap and orthopedic peers and deserving of a higher P/E multiple, especially with upcoming revenue and earnings growth catalysts.
Price Action: ENOV stock is down 2.02% at $40.02 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41171072/amazon-accused-of-union-busting-after-drivers-unionize-nlrb-files-complaint" target="_blank" rel="noreferrer noopener">Amazon Accused of Union-Busting After Drivers Unionize, NLRB Files Complaint</a>.</li>
</ul>

Analyst Color

Initiation

Trading Ideas

Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.75, a high estimate of $65.00, and a low estimate of $50.00. Experiencing a 10.54% decline, the current average is now lower than the previous average price target of $65.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1727956822_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Enovis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enovis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enovis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enovis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Enovis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENOV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enovis analyst ratings.</a>
<h2>Get to Know Enovis Better</h2>
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention &amp; Recovery (P&amp;R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention &amp; Recovery segment.
<h3>Financial Milestones: Enovis's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Enovis's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 22.56%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Enovis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enovis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Enovis's ROA excels beyond industry benchmarks, reaching -0.34%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.43.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Enovis

JMP Securities analyst David Turkaly initiates coverage on Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Market Outperform rating and announces Price Target of $62.

JMP Securities Initiates Coverage On Enovis with Market Outperform Rating, Announces Price Target of $62

Evercore ISI Group analyst Vijay Kumar maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Outperform and lowers the price target from $62 to $58.

Evercore ISI Group Maintains Outperform on Enovis, Lowers Price Target to $58

JP Morgan analyst Robbie Marcus maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Neutral and lowers the price target from $53 to $50.

JP Morgan Maintains Neutral on Enovis, Lowers Price Target to $50

Needham analyst Mike Matson maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $82 to $65.

Needham Maintains Buy on Enovis, Lowers Price Target to $65

Enovis Expects 2024 Adjusted EPS Of $2.62-$2.77 Versus Prior Expectations Of $2.52-$2.67 And Consensus Of $2.62, With Adjusted EBITDA Of $368M-$383M

Enovis Expects 2024 Revenue Of $2.08B-$2.13B Versus Prior Expectations Of $2.06B-$2.16B And Consensus Of $2.119B

Enovis Q2 2024 Adj. EPS $0.62 Beats $0.59 Estimate, Sales $525.160M Miss $526.009M Estimate

Biotech

Enovis Releases AltiVate Reverse Glenoid System

In the latest quarter, 4 analysts provided ratings for Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.75, a high estimate of $82.00, and a low estimate of $53.00. This current average represents a 8.22% decrease from the previous average price target of $76.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1719939713_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Enovis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enovis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Enovis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Enovis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENOV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enovis analyst ratings.</a>
<h2>About Enovis</h2>
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention &amp; Recovery (P&amp;R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention &amp; Recovery segment.
<h3>Financial Milestones: Enovis's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Enovis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.11% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Enovis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.95% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.14%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Enovis's ROA stands out, surpassing industry averages. With an impressive ROA of -1.44%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Enovis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.43.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Enovis Analyst Ratings: What You Need To Know

Evercore ISI Group analyst Vijay Kumar maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Outperform and lowers the price target from $70 to $62.

Evercore ISI Group Maintains Outperform on Enovis, Lowers Price Target to $62

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.
The medical info systems industry comprises companies that develop and market healthcare information systems. These companies offer software and hardware solutions to healthcare providers with secure access to real-time clinical, administrative and financial data in a time-efficient manner. Focus on patient satisfaction, security of patient data and&nbsp; cost control has increased the need for big data, 3D printing, blockchain and artificial intelligence.
The medical sector is one of the major adopters of AI, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster and more accurate diagnosis. One common application of AI has been in diagnostic settings, where it quickly and precisely detects image abnormalities that might be challenging for the human eye to spot.
Several medical device makers are also developing surgical robots with AI integration for complex and specialized procedures. Further, electronic health records, electronic medical records, predictive analytics and real-time alerting have been gaining prominence.
AI systems have been successful in multiple medical imaging use cases, such as detecting mitosis in breast cancer histology images, classifying skin cancer with dermatologist-level accuracy, diagnosing diabetic retinopathy from retinal fundus photographs and predicting cardiovascular risk factors from retinal fundus photographs.
Even though the pandemic is over, the need for contactless services is growing enormously. Within the medical information systems space, the telehealth and remote patient monitoring segments continue to grow at a fast pace.
The Zacks-defined Medical Info Systems Industry is currently in the top 25% of the Zacks Industry Rank. Since it is ranked in the top half of Zacks Ranked Industries, we expect the consulting services industry to outperform the market over the next three to six months.
<h3>Our Top Picks</h3>
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks have seen positive earnings estimate revisions in the last 60 days. Each of our picks carries a Zacks Rank#1 (Strong Buy) or 2 (Buy).
The chart below shows the price performance of our five picks year to date.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/92/69334.jpg?v=194732729" /> 
Image Source: Zacks Investment Research
Hims &amp; Hers Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. HIMS offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
HIMS also provides prescription medication on a recurring basis and ongoing care from healthcare providers, over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
Zacks Rank #1 Hims &amp; Hers Health has an expected revenue and earnings growth rate of 41.9% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 5.6% over the last seven days.
Enovis Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enov#NYSE">ENOV</a>) operates as a medical technology company focused on developing clinically differentiated solutions worldwide. ENOV also manufactures and distributes medical devices that are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. ENOV operates through the Prevention and Recovery, and Reconstructive segments.
Zacks Rank #2 Enovis has an expected revenue and earnings growth rate of 24.4% and 9.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.8% over the last 30 days.
Pulmonx Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lung#NASDAQ">LUNG</a>) is a commercial-stage medical technology company that provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. LUNG offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema, and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
LUNG also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis offering information on emphysema destruction, fissure completeness, and lobar volume to identify target lobes for the treatment with Zephyr Valves.
Zacks Rank #2 Pulmonx has an expected revenue and earnings growth rate of 21.3% and 0.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 8.4% over the last 60 days.
Phreesia Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phr#NYSE">PHR</a>) provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. PHR&#39;s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.
Zacks Rank #2 Phreesia has an expected revenue and earnings growth rate of 17.9% and 53%, respectively, for the current year (ending January 2025). The Zacks Consensus Estimate for current-year earnings has improved 20.3% over the last 30 days.
Standard BioTools Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lab#NASDAQ">LAB</a>) provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. LAB operates through two segments: Proteomics and Genomics.
LAB offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system that performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes, and Hyperion XTi imaging system, a spatial biology instrument.
LAB also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs, and IFC Controllers, a controller which is designed to work with IFC formats.
Zacks Rank #2 Standard BioTools has an expected revenue and earnings growth rate of 89.5% and 43.9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 23.3% over the last 60 days.
<a href="https://www.zacks.com/stock/news/2292098/5-medical-info-systems-stock-to-buy-for-a-stable-portfolio?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2292098">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LUNG

5 Medical Info Systems Stock to Buy for a Stable Portfolio

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>)</h3>
<ul>
<li>On June 13, Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1. The company's stock fell around 28% over the past month and has a <a href="https://www.benzinga.com/quote/RGEN">52-week low of $110.45</a>.</li>
<li>RSI Value: 22.62</li>
<li>RGEN Price Action: Shares of Repligen fell 2.4% to close at $120.00 on Thursday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent062124&amp;t=be2bearmibe3na1">Benzinga Pro's real-time newsfeed</a> alerted to latest RGEN&#8217;s news.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="678" height="744" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034221/Screenshot-2024-06-21-at-1.12.10-PM.png" alt="" class="wp-image-398621" style="width:395px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034221/Screenshot-2024-06-21-at-1.12.10-PM.png 678w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034221/Screenshot-2024-06-21-at-1.12.10-PM-273x300.png 273w" sizes="(max-width: 678px) 100vw, 678px" /></a></figure>
<h3 class="wp-block-heading">Enovis Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On May 2, Enovis posted better-than-expected quarterly results. &#8220;We had a great start to 2024, with both revenues and operating margins exceeding expectations,&#8221; said Matt Trerotola, Chief Executive Officer of Enovis.&#8221; The company's stock fell around 12% over the past month. It <a href="https://www.benzinga.com/quote/ENOV">has a 52-week low</a> of $43.04.</li>
<li>RSI Value: 25.21</li>
<li>ENOV Price Action: Shares of Enovis fell 0.1% to close at $44.56 on Thursday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent062124&amp;t=be2bearmibe3na1">trend in ENOV&#8217;s stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="689" height="745" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034300/Screenshot-2024-06-21-at-1.12.53-PM.png" alt="" class="wp-image-398622" style="width:424px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034300/Screenshot-2024-06-21-at-1.12.53-PM.png 689w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034300/Screenshot-2024-06-21-at-1.12.53-PM-277x300.png 277w" sizes="(max-width: 689px) 100vw, 689px" /></a></figure>
<h3 class="wp-block-heading">Penumbra Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>)</h3>
<ul>
<li>On May 7, Penumbra posted upbeat quarterly earnings. The company's stock fell around 8% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/PEN">low of $170.59</a>.</li>
<li>RSI Value: 28.39</li>
<li>PEN Price Action: Shares of Penumbra fell 0.3% to close at $175.45 on Thursday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent062124&amp;t=be2bearmibe3na1">Benzinga Pro's signals feature</a> notified of a potential breakout in PEN&#8217;s shares.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="660" height="745" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034328/Screenshot-2024-06-21-at-1.13.22-PM.png" alt="" class="wp-image-398624" style="width:439px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034328/Screenshot-2024-06-21-at-1.13.22-PM.png 660w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/21034328/Screenshot-2024-06-21-at-1.13.22-PM-266x300.png 266w" sizes="(max-width: 660px) 100vw, 660px" /></a></figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39414244/over-28m-bet-on-this-energy-stock-check-out-these-3-stocks-insiders-are-buying">Over $28M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying</a>

Long Ideas

Pre-Market Outlook

RGEN

Top 3 Health Care Stocks That Could Blast Off In June

JP Morgan analyst Robbie Marcus initiates coverage on Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Neutral rating and announces Price Target of $53.

JP Morgan Initiates Coverage On Enovis with Neutral Rating, Announces Price Target of $53

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/&quot;">Benzinga Pro</a> .
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)</h3>
<ul>
<li>On May 1, Tevogen Bio announced full year 2023 financial results and upcoming operational objectives. The company's stock fell around 64% over the past month and has a <a href="https://www.benzinga.com/quote/TVGN">52-week low of $0.8030</a> .</li>
<li>RSI Value: 19.57</li>
<li>TVGN Price Action: Shares of Tevogen Bio fell 1% to close at $0.96 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Enovis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On May 2, Enovis posted better-than-expected quarterly earnings. &#8220;We had a great start to 2024, with both revenues and operating margins exceeding expectations,&#8221; said Matt Trerotola, Chief Executive Officer of Enovis. &#8220;Our acquisition of Lima is a transformative milestone and reinforces our ability to innovate and take incremental market share in the global orthopedic market. The integration is progressing according to plan and we remain in the early stages of a multi-year cadence of new product introductions across Recon and P&amp;R.&#8221; The company's stock fell around 17% over the past month. It <a href="https://www.benzinga.com/quote/ENOV">has a 52-week low</a> of $43.04.</li>
<li>RSI Value: 25.09</li>
<li>ENOV Price Action: Shares of Enovis fell 0.7% to close at $50.92 on Monday.</li>
</ul>
<h3 class="wp-block-heading">GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>)</h3>
<ul>
<li>On April 1, GRI Bio reported a FY23 net loss of $13.0 million. &#8220;Over the past several months we&#8217;ve achieved significant regulatory and clinical milestones while adding $5.5 million to the balance sheet, paving the way for an exciting 2024 marked by key data readouts. Our Phase 2a biomarker study for GRI-0621 in IPF is gaining momentum and with interim and topline data expected this year, we believe we have the potential to unlock substantial value for all stakeholders,&#8221; commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. The company's shares fell around 25% over the past month and has a 52-week l<a href="https://www.benzinga.com/quote/GRI">ow of $0.40</a>.</li>
<li>RSI Value: 25.57</li>
<li>GRI Price Action: Shares of GRI Bio rose 0.5% to close at $0.4171 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>On May 6, the U.S. Food and Drug Administration accepted the company's application for subcutaneous nivolumab (nivolumab and hyaluronidase). The company's shares lost around 14% over the past month. The company's 52-week low is $43.33.</li>
<li>RSI Value: 25.22</li>
<li>BMY Price Action: Shares of Bristol-Myers Squibb fell 0.2% to close at $43.90 on Monday.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/05/38661465/investor-optimism-decreases-slightly-but-dow-records-gains-for-4th-day">Investor Optimism Decreases Slightly, But Dow Records Gains For 4th Day</a>

ALPS ETF Trusthen & Steers Global Realty Majors ETF

TVGN

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month

FY24 consensus $2.71. Sees FY24 revenue $2.1B, consensus $2.11B. Sees FY24 adjusted EBITDA $373M-$378M. Published first on TheFly – the ultimate so...

Enovis raises FY24 adjusted EPS view to $2.75-$2.80 from $2.62-$2.77

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript

Needham analyst Michael Matson reiterated a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $65.00. Michael Matson ha...

Enovis's Strong Q3 2024 Performance and Growth Prospects Justify Buy Rating

Enovis Corporation ( ($ENOV) ) has released its Q3 earnings. Here is a breakdown of the information Enovis Corporation presented to its investors. ...

Enovis Corporation Reports Strong Sales Growth in Q3 2024

Enovis (ENOV – Research Report), the Industrials sector company, was revisited by a Wall Street analyst today. Analyst David Turkaly from JMP Secur...

Enovis's Positive Outlook Bolstered by Strong Sales Growth and Strategic Positioning

In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy rating on Enovis (ENOV – Research Report), with a price target of $62....

Wells Fargo Keeps Their Buy Rating on Enovis (ENOV)

Roth MKM analyst Jason Wittes maintained a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $75.00. The company's shar...

Roth MKM Sticks to Their Buy Rating for Enovis (ENOV)

Jeff Johnson, an analyst from Robert W. Baird, maintained the Buy rating on Enovis (ENOV – Research Report). The associated price target is $64.00....

Enovis: Strong Market Position and Growth Potential Justify Buy Rating

RVT: A Small-Cap Equity Fund For Income Investors With A 7.4% Yield And 12% Discount

ATHM

AUDC

CELH

EXAS

GMED

HNDAF

IESC

IONS

IRBT

SEIC

TMDX

VERX

Press Releases

Enovis Announces Time Change for Second Quarter 2024 Results Conference Call

Enovis Announces Second Quarter 2024 Results

Enovis to Participate in Upcoming Investor Conferences

Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability

Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures

Comments

Enovis

Vendite allo scoperto

Enovis (NYSE:ENOV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO